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Abstract
Background The optimal surgical strategy for resectable, synchronous, colorectal liver metastases remains unclear. The
objective of this study was to determine which patients could benefit from staged resections instead of simultaneous
resection by identifying predictive factors for postoperative morbidity and anastomotic leakage after simultaneous resection
of synchronous, colorectal liver metastases and the primary colorectal tumor.
Methods This study involved 86 patients with synchronous colorectal liver metastases who underwent simultaneous
resection of the primary colorectal tumor and the hepatic tumor. Postoperative mortality, morbidity, and other surgical
outcomes, including survival and hospitalization, were assessed. Predictive factors for postoperative morbidity and for
anastomotic leakage were evaluated.
Results Postoperative morbidity and anastomotic leakage were found in 55 (64%) and 18 (21%) patients. Predictive factors
for postoperative morbidity and for anastomotic leakage were intraoperative blood loss and operation time >8 h,
respectively. The overall 5-year survival rate was 45%.
Conclusions The frequency of morbidity and that of anastomotic leakage seemed to be high after simultaneous resection for
synchronous colorectal liver metastases, especially when intraoperative blood loss or operation time increased greatly.
Staged resections should be considered in cases in which excessive surgical stress from simultaneous resection of
synchronous colorectal liver metastases would be expected.
Keywords Colorectal cancer.Hepatic metastasis.Liver
metastasis.Morbidity.Anastomotic leakage
Introduction
For patients with synchronous colorectal liver metastases
(SCLM), hepatic resection is considered the best
treatment, with reported 5-year survival rates between
23% and 37%.
1–4 Resections of both the primary
colorectal lesion and the hepatic metastases are needed
for patients with SCLM when they are resectable.
However, the optimal surgical strategy for resectable
SCLM still remains controversial.
From the perspectives of less operation with less mental
stress and simplifying perioperative treatment, simultaneous
resection of the primary colorectal and liver tumors is a
favorable strategy for patients with SCLM.
5–8 However,
several papers reported that the morbidity rate after
simultaneous resection of primary and liver tumors was
high because of greater surgical stress and a longer
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resection with initial operation for the primary lesion
followed by resection of hepatic tumors is regarded as an
alternative strategy to avoid excessive surgical stress for
patients with SCLM, though the efficacy of this strategy
and the patients who could benefit from this strategy are
unknown.
4–6,9,10
Thus, this study was conducted to determine which
patients could benefit from staged resections instead of
simultaneous resection by identifying predictive factors for
postoperative morbidity and anastomotic leakage after
simultaneous resection of SCLM.
Patients and Methods
Patient Population
The medical records of all consecutive patients who
underwent liver resections for colorectal liver metastases
from January 1992 to January 2004 at our institution
were analyzed retrospectively, with institutional review
board approval. Eighty-six patients had SCLM. During
this period, all SCLM patients received simultaneous
resection of primary colorectal and hepatic tumors
irrespective of the patient's or the tumor's characteristics.
Lateral lymph node dissection was routinely performed in
patients with advanced lower rectal cancer. All 86 patients
underwent contrast enhanced computed tomography (CT)
of the chest, abdomen, and pelvis, as well as hepatic MRI,
preoperatively.
As a control, the morbidity of 167 patients who
underwent hepatectomy for metachronous liver metastasis
from colorectal cancer from January 1992 to January 2004
and that of 1,728 patients who underwent only resection for
colorectal cancer with colorectal reconstruction during the
same period were also reviewed. Of the 1,728 colorectal
cancer patients, 1,319 had colon cancer and 409 had rectal
cancer.
Postoperative Morbidity
Incidences of the following postoperative complications
were analyzed: anastomotic leak, rectovaginal fistula,
intraperitoneal or pelvic abscess, wound infection, wound
dehiscence, ileus, enteroparesis, postoperative delirium,
urinary tract infection, dysuria, empyema thoracis, pleural
effusion, atelectasis, cholecystitis, perihepatic or subphrenic
abscess, bile leak, liver failure, and others. Anastomotic
leakage was defined as follows: peritonitis and a dehiscence
in the anastomosis, discharge of pus from the anus, vaginal
fistula, or feces from the abdominal drain. Leakage was
confirmed by CT scan, contrast enema, re-operation, or
digital rectal examination. All complications were graded
according to the classification proposed by Clavien et al.
11
Postoperative mortality was defined to include any death
during postoperative hospitalization or within 30 days.
Assessment of Predictive Factors for Postoperative
Morbidity
Correlations between postoperative morbidity and the
following patient, tumor, and surgical factors were ana-
lyzed: age, sex, body mass index (BMI), preoperative
comorbidity, site of primary tumor, intestinal obstruction by
tumor, size of primary tumor, differentiation of tumor,
distribution of hepatic tumors, number of hepatic tumors,
hepatic tumor size, operative methods, operation time,
intraoperative blood loss, and blood transfusion.
Survival
Patients were followed regularly at 3-month intervals with
blood testing and CT. Survival and follow-up were
calculated from the time of the operation to the date of
death or last available follow-up. The survivors' median
follow-up time after surgery was 73 months.
Statistical Analysis
Statistical comparisons of baseline data were performed
using the chi-square test. Continuous variables were
compared with the independent t test. Multivariate analyses
to evaluate the independent predictive factors for postoper-
ative complications or anastomotic leakage were done by
multiple logistic regression analysis. The survival rate was
calculated by the Kaplan–Meier method.
12 A difference
was considered significant when p was less than 0.05.
Results
Patients and Operative Details
From 1992 to 2004, 86 patients were treated with
simultaneous resection of primary and hepatic tumors
f o rS C L M .T h e r ew e r e3 7f e m a l ea n d4 9m a l ep a t i e n t s ,
with a median age of 59 years (range, 40 to 85 years).
The site of the primary tumor was colon in 48 and
rectum in 38. The primary tumor was staged as T3 in
54 (63%) and T4 in 32 (37%) according to the TNM
classification. Metastatic lymph nodes were found in 65
patients (76%). The mean diameter of the primary tumor
was 55 mm (range, 26–140 mm).
Liver metastases were solitary in 29 patients and
multiple in 57 patients. In 47 patients (55%), the hepatic
822 J Gastrointest Surg (2012) 16:821–827tumor showed a unilobar distribution, while a bilobar
tumor distribution was observed in 39 (45%). The mean
diameter of the hepatic tumor was about 43 mm (range,
5–200 mm). The mean resected liver volume was 380 g
(range, 10–1,660 g).
The operation for primary colorectal cancer was right
(hemi) colectomy in 17 patients, transverse colectomy in 1,
left (hemi) colectomy in 4, sigmoidectomy in 24, high
anterior resection in 7, low anterior resection in 20, very
low anterior resection in 6, inter-sphincteric resection in 2,
Hartmann's operation in 1, and abdomino-perineal resection
in 4 (Table 4). A diverting stoma to prevent anastomotic
leakage was made in 22 (26%) patients at the surgeon's
discretion, and lateral lymph node dissection was per-
formed in 20 (23%). In terms of liver tumor resection,
lobectomy was performed in 11 patients, segmentectomy in
22, bisegmentectomy in 1, trisegmentectomy in 2, sub-
segmentectomy in 3, and partial resection in 47.
Adjuvant therapy was given to only 17 patients (19.8%)
because adjuvant chemotherapy for colorectal cancer in
stage III or more was performed since January 2003.
Neoadjuvant chemoradiation targeting for rectal cancer was
given to three patients (3.5%).
Morbidity
No patients died within 30 days of the operation, but 55
(64%) patients developed complications (Table 1). Eighteen
patients (21%) experienced leakage, of whom 6 needed
urgent re-operation with ileostomy and drainage of an intra-
abdominal collection caused by leakage. Postoperative
bleeding, wound dehiscence, and ileus were the reasons
for the three other re-operation cases. The most frequent
complication was wound infection.
The morbidity rate of the 167 patients who underwent
hepatectomy for metachronous colorectal liver metastasis
during the same period was 19.8%, and that of 1,728
patients who underwent only resection for colorectal cancer
was 32.1%. Anastomotic leakage occurred in 123 (7.1%) of
the aforementioned 1,728 patients.
Factors Affecting Complications, Especially Anastomotic
Leakage
Postoperative complications were significantly correlated
with presence of diverting stoma (p<0.01), duration of
operation greater than 8 h (p<0.01), amount of intra-
operative blood loss (p<0.01), and intraoperative blood
transfusion (p<0.01). The aforementioned factors were
entered into multivariate analysis. Only a greater amount
of blood loss had a predictive value for increased
occurrence of postoperative complications.
Then, the correlations between anastomotic leakage and
clinicopathological factors were examined to identify risk
factors for anastomotic leakage after simultaneous resection
for SCLM. Patients who underwent abdomino-perineal
Table 1 Postoperative compli-
cations after simultaneous
resection for SCLM according
to Clavien grade
Complications No. of patients Gr I Gr II Gr IIIa Gr IIIb Gr IVa
Colon and rectum
Anastomotic leakage 18 (21%) 12 6
Intrapelvic abscess 6 (7%) 1 4 1
Intraperitoneal abscess 5 (6%) 1 0 3 1
Rectovaginal fistula 4 (5%) 1 3
Liver
Bile leakage 7 (8%) 6 1
Hepatic abscess 7 (8%) 5 1 1
Liver failure 3 (3%) 1 1 1
Postoperative bleeding 1 (1%) 1
Other organs
Wound infection 25 (29%) 23 2
Pleural effusion 12 (14%) 1 11
Wound dehiscence 6 (7%) 3 2 1
Enteroparesis 5 (6%) 5
Postoperative delirium 4 (5%) 1 3
Dysuria 4 (5%) 4
Urinary tract infection 3 (3%) 3
Pneumonia 2 (2%) 2
Others 7 (8%) 1 4 2
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excluded from the analysis. Anastomotic leakage was
significantly correlated with lateral lymph node dissection
(p<0.01), primary site of rectum (p=0.01), duration of
operation greater than 8 h (p<0.01), and amount of
intraoperative blood loss (p=0.02). Neither serum levels
of TP and ALB, steroid usage, nor neoadjuvant therapy
showed correlation with occurrence of anastomotic leakage
(data not shown). Multivariate analyses revealed operation
time greater than 8 h (p<0.01) as the only independent
predictive factor for anastomotic leakage after simultaneous
resection of SCLM (Table 2). Extent of hepatectomy,
timing of anastomosis and hepatectomy, and usage of
Pringle maneuver did not correlate with occurrence of
complication or anastomotic leakage.
Table 3 showed the rates of complication ≥ IIIa and
anastomotic leakage according to operative procedures of
the primary and hepatic resections which were performed in
the same patient. Complication ≥ IIIa and anastomotic
leakage were more frequently observed in patients with
rectal resection; however, extent of hepatectomy did not
seem to affect occurrence of complication ≥ IIIa or anasto-
motic leakage.
Hospitalization was significantly longer in the 55
patients with postoperative morbidity (32.2 days) than in
the 31 patients without postoperative morbidity (17.6 days)
(p<0.01). In addition, hospitalization was significantly
longer in the 18 patients with anastomotic leakage
(43.5 days) than in the 63 patients without anastomotic
leakage (22.2 days) (p<0.01).
Survival
The overall survival rate after simultaneous resection for
SCLM of the 86 patients was 61% at 3 years and 45% at
5 years, with MST of 47 months.
Discussion
For patients with resectable SCLM, both primary tumor
resection and hepatectomy for liver metastasis could lead to
long-term survival, with a 5-year survival rate of 23–37%.
However, the optimal strategy, including surgical resection
and perioperative treatment, remains controversial for
resectable SCLM. In terms of surgical resection for SCLM,
it has not been resolved whether simultaneous resection or
staged resections would be preferable.
There are several rationales for simultaneous resection of
SCLM. In simultaneous resection, the treatment strategy
would become simpler. In the staged resections, a series of
neoadjuvant chemotherapy or chemoradiotherapy, resection
of primary tumor, chemotherapy between two operations,
hepatectomy, and adjuvant chemotherapy could be the
maximal total treatment for SCLM, while simultaneous
resection could simplify and shorten the treatment schedule
by eliminating one operation. Completion of the two
resections and initiation of adjuvant chemotherapy occur
earlier with simultaneous resection than with staged resec-
tions. Considering survival, comparable survival for simulta-
neous resection was shown in comparison with that for staged
resections.
13 Furthermore, simultaneous resection could
relieve patients from a considerable degree of mental and
physical stress and decrease total treatment cost by prevent-
ing a second resection for hepatic metastases. Recent
advances in colorectal and hepatic surgery have enabled
simultaneous resection to be performed more safely. Martin
et al. reported the safety and efficacy of simultaneous
resection. By avoiding a second laparotomy, the overall
complication rate was reduced, and length of hospital stay
was shortened, with no change in operative mortality.
7,8
However, at present, staged resections with initial
resection of the primary tumor followed by hepatic
resection have been frequently performed in patients with
SCLM for several reasons.
4,5,9,10 First, the perioperative
risk of staged resections has been thought to be less than
that of simultaneous resection.
4,13,14 Sheele et al. reported
13 anastomotic leakages of 90 simultaneous procedures in
their series, and two of them led to death.
4 Thelen et al.
proposed the criteria for simultaneous liver resection
according to the age and extent of liver resection, because
death after simultaneous liver resection (n=4) occurred
after major hepatectomies, and three of these four patients
were 70 years of age or older.
15 Second, staged resections
might offer a chance to evaluate liver or extrahepatic
metastases between the two operations. Lambert et al.
reported that staged resections of synchronous hepatic
metastases with an interval of 3 to 6 months might allow
occult disease to become clinically detectable and could
potentially identify patients for whom a hepatic resection
would offer no survival benefit.
10 Fujita recommended an
interval resection to assess the metastatic status of the
regional lymph nodes, because the presence of six or more
lymph node metastases was an independent poor prognostic
factor in patients with resected SCLM and a relative
contraindication for hepatic resection.
9 Some authors
proposed chemotherapy between primary tumor resection
and liver resection to select patients that could benefit from
hepatectomy.
13,16 Alternatively, a liver-first approach of
doing liver resection first and primary resection second was
newly proposed as a strategy for SCLM.
17,18 The liver-first
approach might avoid needless radical colorectal surgery by
confirming curability of hepatic metastases first and also
might increase resectability compared with the ordinary
staged resections especially in patients with progressive
hepatic metastases.







Multivariate analysis p value,
RR (95%CI)
Patient characteristics
Median age (range) (years) 59 (40–85) 59 (41–73) 0.81
Male/female 33/30 12/6 0.42
BMI (mean±SD) 21.9±2.9 22.5±2.2 0.44
Preoperative comorbidity
Absent 44 12 0.78
Present 19 6
Primary colorectal tumor
Site Colon 42 6 0.01 N.S.
Rectum 21 12
Stenosis Absent 56 0 0.34
Present 7 18
Tumor size, mm 52.0 58.0 0.25
pT stage pT3 41 9 0.25
pT4 22 9
pN stage pN0 17 2 0.22
pN+ 46 16
Histology Well, mod 60 15 0.12
Poor 3 3
Liver metastasis
Distribution Unilobar 38 9 0.43
Bilobar 25 9
Number of tumors (range) 2.3 (1–8) 2.6 (1–8) 0.57
Tumor size, mm 47 33 0.06
Operative factors
Lateral lymph node dissection
Absent 55 10 <0.01 N.S.
Present 8 8
Diverting stoma
Absent 48 11 0.24
Present 15 7
Liver resection
Partial Hx, segmentectomy 51 16 0.72
≥Lobectomy 12 2
Timing of anastomosis




Absent 10 1 0.44
Present 53 17
Operation time
<8 h 53 8 <0.01 <0.01, 6.63 (2.09–20.9)
≥8 h 10 10
Blood loss, g (range) 1,345 (162–6,000) 2,487 (430–6,560) 0.02 N.S.
Transfusion
Absent 39 9 0.37
Present 24 9
Blood transfusion, ml 343 1,212 0.05
RR relative risk, CI confidence interval, Hx hepatectomy, N.S. non-significant (p>0.05)
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leakage, after simultaneous resection for SCLM in order to
assess the safety of simultaneous resection. Anastomotic
leakage is sometimes fatal and can cause a difficult situation
with physical and mental discomfort or pain. The morbidity
rate of patients who underwent simultaneous resection for
SCLM seemed to be higher than that of patients with resected
metachronous colorectal hepatic metastasis or that of patients
who underwent only resection for colorectal primary cancer.
Predictive factors for postoperative morbidity and for anasto-
motic leakage were intraoperative blood loss and operation
time greater than 8 h, respectively. The overall morbidity rate
and the rate of anastomotic leakage were 91% and 50%,
respectively, in patients with operation time greater than 8 h,
and 54% and 13%, respectively, in patients with operation
time less than or equal to 8 h. Blood loss and operation time
usually represent the amount of surgical stress. Excessive
surgical stress was possibly correlated with postoperative
morbidity. Hospitalization of patients with complications was
significantly longer than that of patients without complica-
tions. In particular, the average hospitalization of the 18
patients with anastomotic leakage was more than 43 days.
Retrospective studies have also indicated that the occurrence
ofanastomotic leakage isassociatedwith increased morbidity,
mortality, and prolonged hospital stay. Additionally, anasto-
motic leakage may be associated with an increased risk of
local recurrence.
19
Various risk factors for anastomotic leakage have been
analyzed by several investigators. Age, sex, obesity, level
of anastomosis, smoking, blood transfusion, tumor diame-
ter, preoperative (chemo) radiotherapy, physical status,
obstruction, and coronary heart disease have been shown
to be significant risk factors for leakage.
20–24 In simulta-
neous resection for SCLM, not only the factors related to
the tumor, the patient, or the colorectal operation, but
factors related to the hepatectomy could affect the occur-
rence of anastomotic leakage. However, the extent of
hepatic resection, sequence of colectomy, hepatectomy,
anastomosis, use of the Pringle maneuver, and total time
of the Pringle maneuver were not predictive factors for
anastomotic leakage or postoperative complications in
patients with resected SCLM.
Recently, a diverting stoma has been often used to
prevent anastomotic leakage in patients who undergo low
anterior resection by diverting the fecal stream and keeping
the anastomosis free of material.
19,25,26 In this study, the
presence of a diverting stoma was not a predictive factor for
absence of postoperative anastomotic leakage. However,
the analysis estimating efficacy of a diverting stoma in this
study was not accurate, because a diverting stoma was
basically used in patients whose risk for anastomotic
leakage was considered to be high by the surgeons. The
site of primary tumor that has been reported as a strong
predictive factor in previous studies was not a predictive
factor for anastomotic leakage in this series. Use of
diverting stoma might affect the result of analyses of
predictive factors for anastomotic leakage. A randomized,
controlled trial is needed to elucidate the efficacy of a
temporary diverting stoma.
Although several rationales for the simultaneous resec-
tion for SCLM are clear, staged resections should be
selected to prevent anastomotic leakage or serious compli-
cations when the scheduled operation would result in
considerable surgical stress, i.e., predicted operation time
greater than 8 h according to the results of the present
study. Predicted operation time should be calculated by
considering various factors, such as characteristics of the
patient, primary and metastatic tumor, extent of operation,
difficulty of the procedure, and so on. Based on the results
of this study, we now select staged resections when
operation time is expected to be greater than 8 h; otherwise,
we select simultaneous resection. A prospective study of
SCLM to evaluate the efficacy and safety of the operation
time-based decision model is in progress.
Currently, adjuvant chemotherapy is one of the key
factors which could affect prognosis. Then, comparison of
ratio of patients who could receive adjuvant chemotherapy
will be essential when comparing the efficacy of simulta-
neous resection and that of staged resections in a future
study of SCLM. Furthermore, in staged resections, there is
a risk that some patients could not undergo a second
resection after the first resection due to tumor progression
or complication of first surgery. Resection rate of patients
who could undergo both primary and hepatic resections
Table 3 Rates of complication ≥ Gr IIIa and anastomotic leakage according to the site of primary colorectal resection and extent of hepatectomy
Primary colorectal resection Hepatectomy Complication ≥ Gr IIIa Anastomotic leakage
Colectomy <Lobectomy 4/40 (10%) 5/39
a (13%)
≥Lobectomy 0/7 (0%) 1/7 (14%)
Rectal resection <Lobectomy 11/32 (34%) 11/28
b (39%)
≥Lobectomy 2/7 (29%) 1/7 (14%)
aOne patient who underwent Hartmann's operation was excluded from the analysis
bFour patients who underwent abdomino-perineal resection were excluded from the analysis
826 J Gastrointest Surg (2012) 16:821–827should be assessed when comparing simultaneous resection
and staged resections in SCLM.
The limitations of our study are its retrospective design
and the relatively small number of patients studied.
Conclusion
The morbidity rate and the frequency of anastomotic
leakage were high with simultaneous resection for SCLM,
especially in patients with greater intraoperative blood loss
or operation time greater than 8 h. For patients with SCLM,
staged resections should be considered when simultaneous
resection would involve excessive surgical stress.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical
score for predicting recurrence after hepatic resection for
metastatic colorectal cancer: analysis of 1001 consecutive cases.
Ann Surg. 1999;230(3):309–318; discussion 18–21.
2. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K,
Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma
metastases to the liver. A prognostic scoring system to improve
case selection, based on 1568 patients. Association Francaise de
Chirurgie. Cancer. 1996;77(7):1254–1262.
3. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S,
Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of
surgicalindications inthetreatmentoflivermetastasesfromcolorectal
cancer: long-term results. Ann Surg. 2000;231(4):487–499.
4. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of
prognosis after hepatic resection for colorectal secondaries.
Surgery. 1991;110(1):13–29.
5. Capussotti L, Vigano L, Ferrero A, Lo Tesoriere R, Ribero D,
Polastri R. Timing of resection of liver metastases synchronous to
colorectal tumor: proposal of prognosis-based decisional model.
Ann Surg Oncol. 2007;14(3):1143–1150.
6. Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG,
Nagorney DM. Concurrent vs. staged colectomy and hepatectomy
for primary colorectal cancer with synchronous hepatic metastases.
Dis Colon Rectum. 2004;47(8):1310–1316.
7. Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O. Combined
colon and hepatic resection for synchronous colorectal liver
metastases. J Surg Oncol. 2001;78(1):17–21.
8. Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R,
Jarnagin W, Blumgart L. Simultaneous liver and colorectal
resections are safe for synchronous colorectal liver metastasis. J
Am Coll Surg. 2003;197(2):233–41; discussion 41–42.
9. Fujita S, Akasu T, Moriya Y. Resection of synchronous liver
metastases from colorectal cancer. Jpn J Clin Oncol. 2000;30(1):7–11.
10. Lambert LA, Colacchio TA, Barth RJ, Jr. Interval hepatic
resection of colorectal metastases improves patient selection.
Arch Surg. 2000;135(4):473–9; discussion 9–80.
11. Dindo D, Demartines N, Clavien PA. Classification of surgical
complications: a new proposal with evaluation in a cohort of
6336 patients and results of a survey. Ann Surg. 2004;240
(2):205–213.
12. Kaplan E. Nonparametric estimation from incomplete observa-
tions. J Am Stat Assoc. 1958;53:457–481.
13. Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth
H. Role of neoadjuvant chemotherapy in the treatment of
multiple colorectal metastases to the liver. Br J Surg. 2003;90
(8):963–969.
14. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D,
Assumpcao L, Barbas AS, Abdalla EK, Choti MA, Vauthey JN,
Ludwig KA, Mantyh CR, Morse MA, Clary BM. Simultaneous
resections of colorectal cancer and synchronous liver metastases: a
multi-institutional analysis. Ann Surg Oncol. 2007;14(12):3481–
3491.
15. Thelen A, Jonas S, Benckert C, Spinelli A, Lopez-Hanninen E,
Rudolph B, Neumann U, Neuhaus P. Simultaneous versus staged
liver resection of synchronous liver metastases from colorectal
cancer. Int J Colorectal Dis. 2007;22(10):1269–1276.
16. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong
Y. Importance of response to neoadjuvant chemotherapy in
patients undergoing resection of synchronous colorectal liver
metastases. J Gastrointest Surg. 2003;7(1):109–115; discussion
16–7.
17. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth
AD. Neoadjuvant chemotherapy and resection of advanced
synchronous liver metastases before treatment of the colorectal
primary. Br J Surg. 2006;93(7):872–878.
18. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS,
Eggermont AM, de Wilt JH. The “liver-first approach” for
patients with locally advanced rectal cancer and synchronous
liver metastases. Dis Colon Rectum. 2009;52(1):23–30.
19. Karanjia ND, Corder AP, Holdsworth PJ, Heald RJ. Risk of
peritonitis and fatal septicaemia and the need to defunction the
low anastomosis. Br J Surg. 1991;78(2):196–198.
20. Eberl T, Jagoditsch M, Klingler A, Tschmelitsch J. Risk factors
for anastomotic leakage after resection for rectal cancer. Am J
Surg. 2008;196(4):592–598.
21. Jung SH, Yu CS, Choi PW, Kim DD, Park IJ, Kim HC, Kim
JC. Risk factors and oncologic impact of anastomotic leakage
after rectal cancer surgery. Dis Colon Rectum. 2008;51
(6):902–908.
22. Kruschewski M, Rieger H, Pohlen U, Hotz HG, Buhr HJ. Risk
factors for clinical anastomotic leakage and postoperative mortal-
ity in elective surgery for rectal cancer. Int J Colorectal Dis.
2007;22(8):919–927.
23. Lee WS, Yun SH, Roh YN, Yun HR, Lee WY, Cho YB, Chun
HK. Risk factors and clinical outcome for anastomotic leakage
after total mesorectal excision for rectal cancer. World J Surg.
2008;32(6):1124–1129.
24. Rullier E, Laurent C, Garrelon JL, Michel P, Saric J, Parneix M.
Risk factors for anastomotic leakage after resection of rectal
cancer. Br J Surg. 1998;85(3):355–358.
25. Meleagros L, Varty PP, Delrio P, Boulos PB. Influence of
temporary faecal diversion on long-term survival after curative
surgery for colorectal cancer. Br J Surg. 1995;82(1):21–25.
26. Montedori A, Cirocchi R, Farinella E, Sciannameo F, Abraha I.
Covering ileo- or colostomy in anterior resection for rectal
carcinoma. Cochrane Database Syst Rev. 2010(5):CD006878.
J Gastrointest Surg (2012) 16:821–827 827